Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMar 22, 2023Alprazolam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0461-2023Class IITerminatedMar 22, 2023Alprazolam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0460-2023Class IITerminatedMar 22, 2023Alprazolam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0459-2023Class IITerminatedMar 22, 2023Alprazolam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0458-2023Class IIOngoingMar 15, 2023Purely Soothing MSM Nasal SprayCGMP DeviationsPharmedica USA, LLC · D-0457-2023Class IOngoingMar 15, 2023Purely Soothing 15% MSM DropsNon-SterilityPharmedica USA, LLC · D-0456-2023Class IOngoingMar 15, 2023Snowy Range Blue Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-Sterile SolutionChemical Contamination: FDA analysis found the product to contain methanol, acetaldehyde, and acetal above the limits.Nanomaterials Discovery Corporation · D-0455-2023Class IIITerminatedMar 15, 2023DIBUCAINE 1% HEMORRHOIDAL OINTMENTLabeling: Incorrect or Missing Lot and/or Exp DateAkron Pharma, Inc. · D-0454-2023Class IITerminatedMar 15, 2023Unguentine Original Maximum Strength Pain Relieving/Antiseptic OintmentCGMP DEVIATIONSEcometics, Inc. · D-0452-2023Class IITerminatedMar 15, 2023Activator ConcentrateCGMP DEVIATIONSEcometics, Inc. · D-0451-2023Class IITerminatedMar 15, 2023Nose Better GelCGMP DEVIATIONSEcometics, Inc. · D-0450-2023Class IITerminatedMar 15, 2023Soltice Quick-RUBCGMP DEVIATIONSEcometics, Inc. · D-0449-2023Class IITerminatedMar 15, 2023Unguentine Original Ointment for BurnsCGMP DEVIATIONSEcometics, Inc. · D-0448-2023Class IITerminatedMar 15, 2023Vencedor medicated balmCGMP DEVIATIONSEcometics, Inc. · D-0447-2023Class IITerminatedMar 15, 2023Alcolado RelampagoCGMP DEVIATIONSEcometics, Inc. · D-0446-2023Class IITerminatedMar 15, 2023Phenylephrine HCl 20 mgCGMP DEVIATIONSDenver Solutions, LLC DBA Leiters Health · D-0445-2023Class IITerminatedMar 15, 2023Phenylephrine HCl 40 mgCGMP DEVIATIONSDenver Solutions, LLC DBA Leiters Health · D-0444-2023Class IITerminatedMar 15, 2023Phenylephrine HCl 1mg per 10mLCGMP DEVIATIONSDenver Solutions, LLC DBA Leiters Health · D-0443-2023Class IITerminatedMar 15, 2023Phenylephrine HCl 0.5 mg per 5 mLCGMP DEVIATIONSDenver Solutions, LLC DBA Leiters Health · D-0442-2023Class IITerminatedMar 15, 2023Metformin hydrochloride Extended-Release TabletsCGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Teva Pharmaceuticals USA Inc · D-0441-2023Class IIOngoingMar 15, 2023NaturalCareCGMP Deviations: Raw material recalled by repackager, due to discoloration.Nutraceutical Corporation · D-0440-2023Class IIOngoingMar 15, 2023NaturalCare bioAllersCGMP Deviations: Raw material recalled by repackager, due to discoloration.Nutraceutical Corporation · D-0439-2023Class IIOngoingMar 15, 2023NatraBioCGMP Deviations: Raw material recalled by repackager, due to discoloration.Nutraceutical Corporation · D-0438-2023Class IIOngoingMar 15, 2023NaturalCare bioAllersCGMP Deviations: Raw material recalled by repackager, due to discoloration.Nutraceutical Corporation · D-0437-2023Class IITerminatedMar 15, 2023Verapamil Hydrochloride Extended-Release TabletsFailed Dissolution Specification: Out of specification dissolution results at time point zero. The OOS was above specified values.Amerisource Health Services LLC · D-0436-2023Class IITerminatedMar 15, 2023Heparin Sodium InjectionLabeling: Not elsewhere classifiedSagent Pharmaceuticals Inc · D-0435-2023Class IITerminatedMar 15, 2023Heparin SodiumSubpotent Drug: low Anti-Factor IIa potency.B. Braun Medical Inc · D-0434-2023Class IICompletedMar 15, 2023Brimonidine Tartrate Ophthalmic Solution 0.15%Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap...Apotex Corp. · D-0433-2023Class ITerminatedMar 8, 2023PrimeZEN Black 6000 capsuleMarketed Without An Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products...Volt Candy Wholesale Club · D-0453-2023Class IITerminatedMar 8, 2023Carbidopa and Levodopa TabletsPackaging defect: observed packaging defect, blister packaging inadequately sealed.The Harvard Drug Group · D-0432-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 5 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0431-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 4 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0430-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 3 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0429-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 2 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0428-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 1 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0427-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 0.5 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0426-2023Class IITerminatedMar 8, 2023rOPINIRole Tablets USP 0.25 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0425-2023Class IITerminatedMar 8, 2023Pravastatin Sodium Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0424-2023Class IITerminatedMar 8, 2023Pravastatin Sodium Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0423-2023Class IITerminatedMar 8, 2023Pravastatin Sodium Tablets USP 20 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0422-2023